Olesoxime (Trophos) Updates

Olesoxime is a neuro-protective drug that supports the nervous system under stressful conditions. In January 2015, a Phase II clinical trial with young people aged 3 – 25 with SMA Type 2 or 3, indicated that Olesoxime is safe, well tolerated, and able to positively impact disease progression. At the same time, Roche pharmaceutical company agreed to purchase the small, late-stage clinical drug testing company, Trophos that originally developed the drug.

Clinical Trials Now


30th May: Roche Community Update: Olesoxime


23rd January: Roche to buy Trophos


11th March: Trophos Announces Positive Olesoxime Phase II Trial Results


5th April: Olesoxime, A Drug With Potential To Treat SMA, Passes Early Safety Testing

10th June: Recruitment For Phase Two Clinical Trial Now Fully Open

25th March: Announcement Of Phase Two Clinical Trial For SMA Patients